NASDAQ:VRTX - Vertex Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$188.07 +2.35 (+1.27 %)
(As of 02/18/2019 07:07 AM ET)
Previous Close$185.72
Today's Range$185.67 - $188.56
52-Week Range$144.07 - $195.81
Volume1.41 million shs
Average Volume1.60 million shs
Market Capitalization$48.06 billion
P/E Ratio66.46
Dividend YieldN/A
Beta1.65
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for treating cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for treating patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for treating pain; CTX001, which is in Phase I/II trial for treating beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc., as well as a research collaboration with Arbor Biotechnologies to discover DNA endonucleases for cystic fibrosis and four other diseases. It also has a collaboration with X-Chem, Inc. to develop DNA-encoded DEX libraries. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Receive VRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VRTX
CUSIP92532F10
Phone617-341-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.05 billion
Cash Flow$1.0646 per share
Book Value$17.35 per share

Profitability

Net Income$2.10 billion

Miscellaneous

Employees2,300
Market Cap$48.06 billion
OptionableOptionable

Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

How will Vertex Pharmaceuticals' stock buyback program work?

Vertex Pharmaceuticals declared that its Board of Directors has approved a share repurchase program on Thursday, February 1st 2018, which allows the company to repurchase $500,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its quarterly earnings data on Tuesday, February, 5th. The pharmaceutical company reported $1.30 earnings per share for the quarter, beating the consensus estimate of $1.06 by $0.24. The pharmaceutical company had revenue of $870.11 million for the quarter, compared to the consensus estimate of $818.29 million. Vertex Pharmaceuticals had a net margin of 68.81% and a return on equity of 24.15%. The company's revenue was up 33.5% on a year-over-year basis. During the same period last year, the firm posted $0.61 EPS. View Vertex Pharmaceuticals' Earnings History.

When is Vertex Pharmaceuticals' next earnings date?

Vertex Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, April 25th 2019. View Earnings Estimates for Vertex Pharmaceuticals.

What price target have analysts set for VRTX?

17 analysts have issued 12-month price objectives for Vertex Pharmaceuticals' stock. Their forecasts range from $165.71 to $234.00. On average, they anticipate Vertex Pharmaceuticals' stock price to reach $204.6473 in the next twelve months. This suggests a possible upside of 8.8% from the stock's current price. View Analyst Price Targets for Vertex Pharmaceuticals.

What is the consensus analysts' recommendation for Vertex Pharmaceuticals?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 5 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vertex Pharmaceuticals.

What are Wall Street analysts saying about Vertex Pharmaceuticals stock?

Here are some recent quotes from research analysts about Vertex Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Consistent increase in eligible patient population for Vertex’s CF drugs, Kalydeco & Orkambi, is driving sales growth. Vertex’s third CF medicine Symdeko was approved in the United States in February and has been a significant contributor to growth in 2018. Vertex’s CF pipeline is also accelerating rapidly. However, Vertex has faced some challenges with respect to commercialization of Orkambi in ex-U.S. markets due to re-imbursement hurdles. Meanwhile, since Symdeko’s launch, Orkambi revenues are being hurt by patient switch to Symdeko. Also, competitive pressure is rising in the CF market with many other companies developing triple combo CF medicines. The company has a positive record of earnings surprises in the recent quarters and estimates have gone up ahead of Q4 earnings release." (1/26/2019)
  • 2. Cantor Fitzgerald analysts commented, ". Reiterate overweight and $217 price target. This morning, Vertex announced that CFO Tom Graney has resigned effective immediately. He joined 2017, so his tenure was relatively short." (12/17/2018)

Has Vertex Pharmaceuticals been receiving favorable news coverage?

News stories about VRTX stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vertex Pharmaceuticals earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave headlines about the pharmaceutical company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term.

Who are some of Vertex Pharmaceuticals' key competitors?

Who are Vertex Pharmaceuticals' key executives?

Vertex Pharmaceuticals' management team includes the folowing people:
  • Mr. Jeffrey Marc Leiden, Chairman, CEO & Pres (Age 63)
  • Dr. David M. Altshuler, Chief Scientific Officer & Exec. VP of Global Research (Age 54)
  • Mr. Michael J. Parini, Exec. VP and Chief Legal & Admin. Officer (Age 44)
  • Mr. Amit K. Sachdev, Exec. VP & Chief Regulatory Officer (Age 51)
  • Mr. Thomas Graney, Exec. (Age 54)

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.67%), Jennison Associates LLC (2.72%), Oregon Public Employees Retirement Fund (1.80%), Geode Capital Management LLC (1.20%), Northern Trust Corp (1.13%) and Bank of New York Mellon Corp (0.86%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle and Thomas Graney. View Institutional Ownership Trends for Vertex Pharmaceuticals.

Which institutional investors are selling Vertex Pharmaceuticals stock?

VRTX stock was sold by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Prudential Financial Inc., Orbimed Advisors LLC, State of Tennessee Treasury Department, BlackRock Inc., 1832 Asset Management L.P., Two Sigma Investments LP and Standard Life Aberdeen plc. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle and Thomas Graney. View Insider Buying and Selling for Vertex Pharmaceuticals.

Which institutional investors are buying Vertex Pharmaceuticals stock?

VRTX stock was purchased by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Jennison Associates LLC, Thrivent Financial for Lutherans, Two Sigma Advisers LP, Geode Capital Management LLC, Assenagon Asset Management S.A., Candriam Luxembourg S.C.A. and Baillie Gifford & Co.. View Insider Buying and Selling for Vertex Pharmaceuticals.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $188.07.

How big of a company is Vertex Pharmaceuticals?

Vertex Pharmaceuticals has a market capitalization of $48.06 billion and generates $3.05 billion in revenue each year. The pharmaceutical company earns $2.10 billion in net income (profit) each year or $2.83 on an earnings per share basis. Vertex Pharmaceuticals employs 2,300 workers across the globe.

What is Vertex Pharmaceuticals' official website?

The official website for Vertex Pharmaceuticals is http://www.vrtx.com.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]


MarketBeat Community Rating for Vertex Pharmaceuticals (NASDAQ VRTX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,250 (Vote Outperform)
Underperform Votes:  675 (Vote Underperform)
Total Votes:  1,925
MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel